1. Pulmonary metastases of fibrosarcomatous dermatofibrosarcoma protuberans respond to apatinib-based angiogenesis and chemotherapy: a case report
- Author
-
Shouyue Zhang, Zhenyu Ding, Xiang Wen, Yan Zhang, You Lu, Yongmei Liu, Hui-Min Chen, Juan Huang, and Feng Peng
- Subjects
0301 basic medicine ,Chemotherapy ,business.industry ,Angiogenesis ,medicine.medical_treatment ,Case Report ,General Medicine ,Malignancy ,medicine.disease ,Metastasis ,03 medical and health sciences ,chemistry.chemical_compound ,Antiangiogenesis Therapy ,030104 developmental biology ,0302 clinical medicine ,chemistry ,030220 oncology & carcinogenesis ,medicine ,Cancer research ,Dermatofibrosarcoma protuberans ,Apatinib ,business ,Fibrosarcomatous Dermatofibrosarcoma Protuberans - Abstract
Dermatofibrosarcoma protuberans (DFSP) is soft tissue malignancy which is locally aggressive, slow-growth, rarely metastasizing but recurs frequently after surgical excision. Fibrosarcomatous dermatofibrosarcoma protuberans (FS-DFSP) is a variant of DFSP with a higher risk of recurrence and metastasis. For treatment of metastatic DFSP, antiangiogenesis therapy is an important therapeutic option, which is beneficial in increasing the efficacy of chemotherapy. Apatinib is a novel vascular endothelial growth factor receptor 2 (VEGFR-2) inhibitor and revealed potential anti-tumor efficacy in some types of sarcomas. However, there is still no report of apatinib as an angiogenesis therapy for metastatic DFSP to date. Herein we first describe a case of FS-DFSP relapsed and metastasized post multiple surgeries and adjuvant radiotherapy responded to apatinib in combination with chemotherapy, indicating apatinib may be a potential therapeutic option for metastatic DFSP.
- Published
- 2019